Maintenance therapy for multiple myeloma.
Multiple myeloma (MM) is a neoplasm typical of the elderly, with median age at diagnosis of 70 years, and approximately 65% of patients older than 65 years. Many advances have been made thanks to the use of autologous hematopoietic stem cell transplantation (AHSCT) and the introduction of the immunomodulatory drugs and the proteasome inhibitors. Incorporation of novel agents into induction has resulted in improved overall survival. Optimal MM maintenance therapy should maintain or increase response after induction and, when possible, AHSCT. Optimal maintenance therapy must be effective with minimal toxicity and should be easily administered.